John Newman
Stock Analyst at Canaccord Genuity
(2.17)
# 2,677
Out of 4,712 analysts
82
Total ratings
47.14%
Success rate
-8.68%
Average return
Main Sectors:
Stocks Rated by John Newman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Initiates: Hold | $165 | $714.47 | -76.91% | 16 | Dec 17, 2024 | |
| BNTX BioNTech SE | Maintains: Buy | $171 | $114.13 | +49.83% | 7 | Nov 18, 2024 | |
| MCRB Seres Therapeutics | Maintains: Buy | $10 | $0.96 | +941.67% | 9 | Nov 14, 2024 | |
| ATRA Atara Biotherapeutics | Maintains: Buy | $13 → $21 | $13.33 | +57.54% | 3 | Nov 13, 2024 | |
| DCTH Delcath Systems | Maintains: Buy | $21 | $11.34 | +85.19% | 1 | Oct 18, 2024 | |
| ACLX Arcellx | Maintains: Buy | $85 → $115 | $77.58 | +48.23% | 8 | Oct 17, 2024 | |
| ACET Adicet Bio | Maintains: Buy | $19 → $8 | $0.92 | +773.17% | 6 | Sep 11, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $35 → $14 | $2.09 | +569.86% | 2 | Aug 8, 2024 | |
| MRUS Merus | Maintains: Buy | $67 | $42.41 | +57.98% | 2 | Jul 25, 2024 | |
| RNAC Cartesian Therapeutics | Maintains: Buy | $38 → $43 | $18.47 | +132.81% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $6 | $0.25 | +2,300.00% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $11 | $3.03 | +263.04% | 1 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.97 | +415.46% | 2 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $44 | $34.19 | +28.69% | 9 | Feb 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,720 → $400 | $7.79 | +5,034.79% | 4 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $380 → $100 | $2.17 | +4,508.29% | 2 | Apr 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $220 | $5.48 | +3,914.60% | 3 | Jun 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $38 | $14.30 | +165.73% | 2 | Oct 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $27 | $4.76 | +467.82% | 2 | Sep 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Speculative Buy | n/a | $8.98 | - | 1 | Sep 13, 2017 |
Regeneron Pharmaceuticals
Dec 17, 2024
Initiates: Hold
Price Target: $165
Current: $714.47
Upside: -76.91%
BioNTech SE
Nov 18, 2024
Maintains: Buy
Price Target: $171
Current: $114.13
Upside: +49.83%
Seres Therapeutics
Nov 14, 2024
Maintains: Buy
Price Target: $10
Current: $0.96
Upside: +941.67%
Atara Biotherapeutics
Nov 13, 2024
Maintains: Buy
Price Target: $13 → $21
Current: $13.33
Upside: +57.54%
Delcath Systems
Oct 18, 2024
Maintains: Buy
Price Target: $21
Current: $11.34
Upside: +85.19%
Arcellx
Oct 17, 2024
Maintains: Buy
Price Target: $85 → $115
Current: $77.58
Upside: +48.23%
Adicet Bio
Sep 11, 2024
Maintains: Buy
Price Target: $19 → $8
Current: $0.92
Upside: +773.17%
Allogene Therapeutics
Aug 8, 2024
Maintains: Buy
Price Target: $35 → $14
Current: $2.09
Upside: +569.86%
Merus
Jul 25, 2024
Maintains: Buy
Price Target: $67
Current: $42.41
Upside: +57.98%
Cartesian Therapeutics
Jul 3, 2024
Maintains: Buy
Price Target: $38 → $43
Current: $18.47
Upside: +132.81%
May 16, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $0.25
Upside: +2,300.00%
May 9, 2024
Maintains: Buy
Price Target: $12 → $11
Current: $3.03
Upside: +263.04%
Jun 23, 2023
Reiterates: Buy
Price Target: $5
Current: $0.97
Upside: +415.46%
Feb 16, 2022
Maintains: Buy
Price Target: $52 → $44
Current: $34.19
Upside: +28.69%
Aug 10, 2021
Downgrades: Hold
Price Target: $1,720 → $400
Current: $7.79
Upside: +5,034.79%
Apr 9, 2019
Maintains: Buy
Price Target: $380 → $100
Current: $2.17
Upside: +4,508.29%
Jun 13, 2018
Maintains: Buy
Price Target: $210 → $220
Current: $5.48
Upside: +3,914.60%
Oct 17, 2017
Maintains: Buy
Price Target: $30 → $38
Current: $14.30
Upside: +165.73%
Sep 13, 2017
Maintains: Buy
Price Target: $12 → $27
Current: $4.76
Upside: +467.82%
Sep 13, 2017
Downgrades: Speculative Buy
Price Target: n/a
Current: $8.98
Upside: -